Notwithstanding positive clinical evidence, copyright's Vyndamax, a treatment for hereditary transthyretin-mediated amyloidosis (hATTR), is experiencing significant opposition from pharmacy benefit managers. The organizations are often building barriers to coverage, like high expense restrictions